The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer Research

• Publication date

  2001-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11559560
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids

  2000cited by this paper
• Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

  2000cited by this paper
• Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches

  2000cited by this paper
• HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.

  2000cited by this paper
• MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets.

  2000cited by this paper
• Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

  1999cited by this paper
• Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.

  1999cited by this paper
• Dendritic cell vaccines for cancer immunotherapy.

  1999cited by this paper
• Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells.

  1999cited by this paper
• Generation of Functional Human Dendritic Cells From Adherent Peripheral Blood Monocytes by CD40 Ligation in the Absence of Granulocyte-Macrophage Colony-Stimulating Factor

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.

  1998cited by this paper
• Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor.

  1998cited by this paper
• Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.

  1997cited by this paper
• Vaccination of melanoma patients with peptide-pulsed dendritic cells: 047

  1997cited by this paper
• Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin.

  1997cited by this paper
• Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

  1996cited by this paper
• MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines

  1995cited by this paper
• Cellular mucins: targets for immunotherapy.

  1994cited by this paper
• Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.

  1994cited by this paper
• Immunoscintigraphy of human mammary carcinoma xenografts using monoclonal antibodies 12H12 and BM-2 labeled with 99mTc and radioiodine.

  1994cited by this paper
• Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

  1989cited by this paper
• A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomas

  1989cited by this paper
• Phenotypic analysis of human myeloma cell lines

  1989cited by this paper
• B‐cell lymphoma marking only with anti‐epithelial. Membrane antigen

  1989cited by this paper
• Phenotypic analysis of human myeloma cell lines.

  1989cited by this paper
• Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen.

  1988cited by this paper
• A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats.

  1988cited by this paper
• Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis.

  1988cited by this paper

• Dendritic Cell-Cytokine-Induced Killer Cells Co-Loaded with WT1/MUC1/Poly(I:C) Enhance Antitumor Immune Responses In Vitro and In Vivo

  2025cites this paper
• Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy

  2024cites this paper
• MALAT1/miR-582-5p/GALNT1/MUC1 axis modulates progression of AML leukemia stem cells by regulating JAK2/STAT3 pathway

  2024cites this paper
• The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens.

  2023cites this paper
• Overexpression miR-520a-3p inhibits acute myeloid leukemia progression via targeting MUC1

  2022cites this paper
• Tumour‐associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles

  2022cites this paper
• Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors.

  2022cites this paper
• Metabolic Symbiosis‐Blocking Nano‐Combination for Tumor Vascular Normalization Treatment

  2022cites this paper
• A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesian and ABC Analysis

  2022cites this paper
• Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

  2021cites this paper
• Therapeutic dendritic cell cancer vaccines in hematologic malignancies

  2021cites this paper
• Immunotherapeutic Strategies for Multiple Myeloma

  2020cites this paper
• The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression

  2020cites this paper
• Design, Synthesis, and Preliminary Immunological Studies of MUC1-Based Antitumor Vaccines Adjuvanted with R- and S-FSL-1.

  2020cites this paper
• Molecular imaging and deep learning analysis of uMUC1 expression in response to chemotherapy in an orthotopic model of ovarian cancer

  2020cites this paper
• Don’t sugarcoat it: How glycocalyx composition influences cancer progression

  2019cites this paper
• Inverting family GH156 sialidases define an unusual catalytic motif for glycosidase action

  2019cites this paper
• Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.

  2019cites this paper
• Intracellular targets as source for cleaner targets for the treatment of solid tumors.

  2019cites this paper
• Host tissue determinants of tumour immunity

  2019cites this paper
• Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients

  2019cites this paper
• Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma

  2018cites this paper
• Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’

  2018cites this paper
• Multiple Roles of Glycans in Hematological Malignancies

  2018cites this paper
• MUC1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism

  2018cites this paper
• The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells

  2018cites this paper
• Efficacy of intracellular immune checkpoint-silenced DC vaccine

  2018cites this paper
• Cytotoxic T lymphocytes promote cytarabine-induced acute myeloid leukemia cell apoptosis via inhibiting Bcl-2 expression

  2017cites this paper
• Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

  2017cites this paper
• In vitro generation of cytotoxic T cells with potential for adoptive tumour immunotherapy

  2017cites this paper
• Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.

  2017cites this paper
• Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.

  2017cites this paper
• Immunotherapy Strategies Against Multiple Myeloma

  2017cites this paper
• Exploiting poly(I:C) to induce cancer cell apoptosis

  2017cites this paper
• HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

  2016cites this paper
• Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses.

  2016cites this paper
• Precision glycocalyx editing as a strategy for cancer immunotherapy

  2016cites this paper
• MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia

  2016cites this paper
• EMA ) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma

  2016cites this paper
• MUC1 in hematological malignancies

  2016cites this paper
• Effects of the multiple O-glycosylation states on antibody recognition of the immunodominant motif in MUC1 extracellular tandem repeats

  2016cites this paper
• Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis

  2016cites this paper
• LYMPHOID NEOPLASIA Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma

  2015cites this paper
• MUC1 (CD227): a multi-tasked molecule

  2015cites this paper
• AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells

  2015cites this paper
• T cell‐based targeted immunotherapies for patients with multiple myeloma

  2015cites this paper
• Peptide-based immunotherapy in multiple myeloma

  2015cites this paper
• The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

  2015cites this paper
• Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.

  2015cites this paper
• MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

  2014cites this paper
• The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.

  2014cites this paper
• Immunotherapy for multiple myeloma

  2014cites this paper
• Cell Surface-Associated Anti-MUC1-Derived Signal Peptide Antibodies: Implications for Cancer Diagnostics and Therapy

  2014cites this paper
• Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

  2014cites this paper
• RNAVaccines in Cancer Treatment

  2014cites this paper
• MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice.

  2014cites this paper
• MUC 1 IS A POTENTIAL TARGET FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA STEM CELLS

  2014cites this paper
• Electroporation of dendritic cells with autologous total RNA from tumor material.

  2014cites this paper
• MYELOID NEOPLASIA MUC 1-C oncoprotein promotes FLT 3 receptor activation in acute myeloid leukemia cells

  2014cites this paper
• Biological Therapy for Multiple Myeloma

  2014cites this paper
• T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.

  2013cites this paper
• Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line.

  2013cites this paper
• Cellular Immunotherapy Using Dendritic Cells in Multiple Myeloma: New Concept to Enhance Efficacy

  2013cites this paper
• Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.

  2013cites this paper
• Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors.

  2013cites this paper
• Protein 1 Transcription Factors by Multiple I-Binding Factor 1 and X Box-Binding Targeting Positive Regulatory Domain

  2013cites this paper
• Advances in immunotherapy of chronic myeloid leukemia CML.

  2013cites this paper
• Tumor and Stem Cell Biology MUC 1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells

  2013cites this paper
• MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.

  2013cites this paper
• patients with relapsed and measurable disease: a pilot study clinical and immunologic responses in indolent B-cell lymphoma Vaccination with autologous tumor-loaded dendritic cells induces

  2013cites this paper
• IMMUNOBIOLOGY T cells expressing CD 123-speci fi c chimeric antigen receptors exhibit speci fi c cytolytic effector functions and antitumor effects against human acute myeloid leukemia

  2013cites this paper
• Can immunotherapy specifically target acute myeloid leukemic stem cells?

  2013cites this paper
• Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy.

  2013cites this paper
• Identification of human leucocyte antigen (HLA)‐A*0201‐restricted cytotoxic T lymphocyte epitopes derived from HLA‐DOβ as a novel target for multiple myeloma

  2013cites this paper
• Award Number: W81XWH-11-1-0040 TITLE: The Role of IDO in Muc1 Targeted Immunotherapy PRINCIPAL INVESTIGATOR: Dahlia Besmer CONTRACTING ORGANIZATION: The University of North Carolina at Charlotte

  2013cites this paper
• Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues.

  2013cites this paper
• Antibody-directed double suicide gene therapy targeting of MUC1- positive leukemia cells in vitro and in vivo.

  2013cites this paper
• Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.

  2013cites this paper
• Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

  2012cites this paper
• MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge

  2012cites this paper
• Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.

  2012cites this paper
• Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

  2012cites this paper
• Generation of lymphocytes potentiated against leukemic lymphoblasts by stimulation using leukemic cell lysate-pulsed dendritic cells in patients with acute lymphoblastic leukemia and measurement of in vitro anti-leukemic cytotoxicity

  2012cites this paper
• Cellular immunotherapy using dendritic cells against multiple myeloma

  2012cites this paper
• The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors

  2012cites this paper
• Development of an Effective Therapy for CML

  2012cites this paper
• Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.

  2012cites this paper
• Dendritic/tumor fusion cells as cancer vaccines.

  2012cites this paper
• Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

  2012cites this paper
• Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?

  2012cites this paper
• Immunotherapeutical approaches for multiple myeloma

  2012cites this paper
• Microparticle Dissemination of Biological Activities: Implications for Cancer Biology

  2012cites this paper
• Natural and Induced Humoral Responses to MUC1

  2011cites this paper
• MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells.

  2011cites this paper
• Recognition of pleural mesothelioma by mucin-1(950–958)/human leukocyte antigen A*0201-specific CD8+ T-cells

  2011cites this paper
• PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

  2011cites this paper
• Active and Adoptive Immunotherapy in Indolent Lymphoproliferative Diseases

  2011cites this paper
• Mixed-phase synthesis of glycopeptides using a N-peptidyl-2,4-dinitrobenzenesulfonamide-thioacid ligation strategy.

  2011cites this paper
• Development of an Effective Therapy for Chronic Myelogenous Leukemia

  2011cites this paper
• Aberrant overexpression of membrane-associated mucin contributes to tumor progression in adult T-cell leukemia/lymphoma cells

  2011cites this paper